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Cervical cancerce that high-risk human papillomaviruses (HPV) can cause cervical cancer.
Strikingly, HPV16 and 18 account for ∼70% of all cervical cancers, whereas phylogenetically related types are
found at much lower frequencies. Most likely, differences in the activities of the viral E6 and E7 oncoproteins
account for the in vivo carcinogenicity. We demonstrate here that E6 proteins from low-risk HPV70 and
possibly high-risk HPV82 interact and degrade PDZ proteins hDlg and Magi1 identical to HPV16E6 and
HPV18E6. In contrast high-risk HPV66E6 did not bind or degrade hDlg or Magi1. We also show that low-risk
HPV70 E6/E7 immortalizes normal human keratinocytes. Together with our previous analysis concerning
p53 degradation, this shows that neither binding of E6 to p53, to E6AP, to Magi1 and hDlg, the degradation of
hDlg and Magi1, nor immortalization of normal human keratinocytes seems to be a reliable predictor for
carcinogenic behavior of HPV in the cervix.
© 2009 Elsevier Inc. All rights reserved.Introduction
Molecular and epidemiologic studies have provided compelling
evidence that infections with human papillomavirus (HPV) type 16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 or 66 are a necessary risk factor
for the development of cervical cancer (Cogliano et al., 2005; zur
Hausen, 2002). In contrast, infections with other HPV types such as 6
or 11 do not contribute to cervical cancer development (Cogliano et
al., 2005). In order to understand why certain HPV types are
carcinogenic in vivo while others are not, the activities of the most
prevalent carcinogenic high-risk types HPV16 and 18 have been
compared to the low-risk HPV6 and 11. These studies have resulted in
the concept that the major determinants for cancer development by
HPV are the activities of the early proteins E6 and E7 (Munger et al.,
2004; Munger and Howley, 2002; zur Hausen, 2002). E6 and E7 are
the only HPV proteins that are consistently expressed in cervical
cancer cells and interference with their expression results in growth
inhibition of established cervical cancer cell lines such as HeLa
(Munger et al., 2004; Munger and Howley, 2002; zur Hausen, 2002).
Furthermore, only E6 and E7 derived fromhigh-risk HPV16 and 18, but
not from low-risk HPV6 or 11 display oncogenic behavior in cell
culture based assays such as immortalization of normal human cellse (T. Iftner).
ll rights reserved.and transgenic mouse models (Munger et al., 2004; Munger and
Howley, 2002; zur Hausen, 2002). The oncogenic activities of high risk
HPV16 and 18 E6 and E7 proteins aremediated by the recruitment of a
large number of host cell proteins. HPV16 and 18 E7 bind to all
members of the retinoblastoma protein family (pRb, p107, p130) who
control cell cycle progression and differentiation (Munger et al.,
2004). Low-risk HPV6 and 11 E7 also interact with pRb family
members albeit with a lower afﬁnity and, in contrast to 16 E7 and 18
E7, only induce the proteolytic degradation of p130 (Munger et al.,
1989; Zhang et al., 2006). Furthermore, the E6 proteins of HPV16 and
18 behave very different from those of HPV6 and 11 in the following
ways. Firstly, only E6 proteins of HPV16 and 18, but not of 6 or 11
interact with the p53 tumor suppressor protein and induce its
proteolytic degradation by recruiting the E3 ubiquitin ligase E6AP
(Scheffner et al., 1990). Secondly, the HPV16 E6 protein has been
shown to induce telomerase activity (Klingelhutz et al., 1996). Both
functions, as well as the impact of E6 on the transcriptional changes in
HPV-positive cells were reported to be dependent on E6AP (Kelley et
al., 2005; Liu et al., 2005). Initially, E6AP was described only to bind to
high-risk E6 protein, whereas recent studies reported an interaction
with the E6 proteins of the low-risk HPV 11 (Kuballa et al., 2007).
Finally, 16 E6 and 18 E6 proteins share a conserved carboxyterminal
domain, not present in 6 E6 and 11 E6, which has been shown to
mediate the interaction with PDZ (PSD-95, Dlg, Zo-1) domain
containing proteins such as hDlg, Magi1 and hScrib (Gardiol et al.,
1999; Glaunsinger et al., 2000; Kiyono et al., 1997; Lee et al., 1997;
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tight junctions, where hDLG associates with E-cadherin (Laprise et al.,
2004) and Magi1 with β-catenin (Dobrosotskaya and James, 2000).
Furthermore, hDLG can inhibit cell cycle progression by interaction
with the adenomatous polyposis coli protein (Ishidate et al., 2000)
and Magi1 was shown to interact with PTEN, thereby reducing cell
invasiveness (Kotelevets et al., 2005). Importantly, deletion analyses
revealed that the PDZ binding domain (PDZBD) of 16 E6 is not
involved in binding to and degradation of p53 (Elbel et al., 1997; Foster
et al., 1994). The biological function of the PDZBD of E6 is, however,
only partially understood. E6 PDZBD deletion mutant failed to induce
hyperplasia in transgenic mice (Nguyen et al., 2003). In tissue culture
the PDZBD of 16 E6 is required for the transformation of rodent cells
(Kiyono et al., 1997), contributes to an antiapoptotic activity of 16 E6
(James et al., 2006) and is involved in the anchorage independent
growth of human tonsil epithelial cells (Spanos et al., 2008).
Furthermore, mutation of the PDZBD of high-risk HPV31 E6 in the
context of the HPV31 genome inﬂuenced viral copy number and the
growth rate of immortalized cells (Lee and Laimins, 2004). In
summary, these results suggest that the PDZBD of E6 may contribute
to the carcinogenic potential of HPV in vivo independently from p53
and telomerase by binding to PDZ-proteins like Magi1, hDlg or hScrib.
Phylogenetic analyses revealed that the currently accepted high-
risk HPV types 16,18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 66 belong
to speciesα5,α6,α7 andα9 (de Villiers et al., 2004; Narechania et al.,
2005). Interestingly, HPV types 26, 30, 53, 67, 68, 69, 70, 82 and 85 are
also included in these species, but are currently not classiﬁed or areFig. 1. In vitro degradation of Magi1c and hDlg by different E6 proteins. (A) Identical amounts
in vitro translated 35S-labeled Magi1c or hDlg and the remaining proteins were analyzed by SD
(B) or hDlg (C) as shown in (A). Values are presented relative to the amount ofMagi1c or hDlg
three independent experiments and the error bars indicate the error of the mean. Low riskregarded as low-risk (Munoz et al., 2003, 2006). Among these virus
types, HPV70 is particularly interesting as it is closely related to
HPV18, but occurs in cervical cancer at frequencies at the level of the
low-risk types HPV6 and 11 and appears to be present only together
with carcinogenic types (Herrero et al., 2005; Munoz et al., 2006;
Smith et al., 2007). This strongly suggests that HPV70 has no or only
very limited abilities to induce cervical cancer in vivo. Furthermore,
out of the 13 high-risk types, HPV16 and 18 are together responsible
for ∼70% of squamous cell carcinomas and adenomacarcinomas of the
cervix. This strongly suggests that HPV16 and 18 have unique
oncogenic activities in contrast to other high-risk HPVs and related
viruses that are low-risk. Therefore, comparative analyses of HPVs
from species α5, α6, α7 and α9 should allow pinpointing the
molecular mechanisms that account for the development of invasive
cervical cancer in vivo.
In an attempt to understand the molecular basis for the in vivo
carcinogenicity of HPV we have started a comparative analysis of the
E6 functions of 19 different HPV types and the immortalizing activities
of the corresponding HPV types in normal human keratinocytes
(Hiller et al., 2006). This demonstrated that the degradation of p53 by
E6 proteins is not only a feature of carcinogenic high-risk HPV types,
but occurred also with the E6 proteins of HPV70, 53 and 82, which
have been classiﬁed as low-risk or possibly carcinogenic, respectively
(Hiller et al., 2006).
In this report we have extended our analysis to the binding
properties of E6 proteins of a large number of HPV types with respect
to the PDZ domain proteins Magi1 and hDlg. We ﬁnd that many E6of E6 proteins determined as described in Materials and methods were incubated with
S-PAGE and phosphoimaging. (B and C) Quantitation of several experiments for Magi1c
in the presence of water-primed reticulocyte lysate and represent the average of at least
classiﬁed HPV types are indicated by grey, high risk types by black rectangles.
Fig. 2. Interaction of E6 proteins with different target proteins in cell lysates. (A) Similar
amounts of afﬁnity-puriﬁed MBP or MBP-E6 proteins derived from HPV6, 11, 16, 18, 54,
56, 58, 61, 66, 70 and 82 were incubated with whole cell extracts and extensively
washed. Retained proteins were eluted with amylose and then analyzed by
immunoblotting with speciﬁc antibodies against p53, E6AP, hDlg or Magi1. Arrowheads
indicate the presence of higher-molecular weight forms of p53 and E6AP. Experiments
were repeated at least three times with independent MBP fusion protein and whole cell
lysate preparations to ensure reproducibility. (B) MBP or MBP-E6 fusion proteins
derived fromHPV11,16,18, 56, 66 and 70were tested for their interactionwith hScrib by
immunoblotting as described above.
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neither restricted to high-risk HPV types nor a common feature of all
high-risk types as HPV66 E6 neither binds nor degrades hDlg, Magi1
or hScrib. These ﬁndings together with our previously published
results (Hiller et al., 2006) strongly indicate that neither binding of E6
to p53, to E6AP, to the PDZ domain proteins Magi1 and hDlg nor the
immortalization of normal human foreskin keratinocytes seems to be
a sole predictor for carcinogenic behavior of HPV in the cervix.
Results
In vitro degradation of PDZ domain proteins hDlg and Magi1 by
E6 proteins
In order to investigate the correlation between the carcinogenic
potential of HPV in vivo and E6 activities, we performed in vitro
degradation assays with E6 target proteins hDlg and Magi1c as
previously described for p53 (Hiller et al., 2006). E6 proteins from 20
different HPV types including the accepted high-risk types 16, 18, 33,
35, 39, 45, 51, 52, 56, 58 and 66 as well as low-risk, not fully
characterized or possibly high-risk types 6,11, 42, 44, 53, 54, 61, 70 and
82 were in vitro translated and mixed with in vitro translated,
radioactively-labeled hDlg or Magi1c protein (Fig. 1A). The expression
of the E6 proteins was conﬁrmed previously (Hiller et al., 2006). In
line with published results the E6 proteins of HPV16 and 18, but not of
low-risk HPV6 and 11 were able to induce the degradation of Magi1c
(Fig. 1B) (Glaunsinger et al., 2000). In addition, the E6 proteins from
the high-risk types HPV33, 35, 39, 45, 51, 52 and 58 were also able to
reduce the amounts of Magi1c. Interestingly, this was also the case for
the E6 proteins from types 53 and 82 (possibly high-risk) and low-risk
type 70. In contrast, the E6 proteins of low-risk HPV42, 44, 54, 61 and
of high-risk HPV 56 and 66 did not decrease Magi1c levels. Using hDlg
as a second PDZBD in vitro degradation target for E6 proteins revealed
a strong reduction of hDlg by E6 proteins of high-risk HPV18, 35, 39, of
low risk HPV70 and of the possibly high risk HPV82 and a moderate
reduction by E6 proteins of high-risk HPV16, 33, 45 and 51 (Fig. 1C). In
contrast, no change in the protein levels of hDlg was observed with E6
proteins of low-risk HPV6,11, 42, 44, 54, 61, of high risk HPV 52, 56, 58,
66 and the possibly high-risk HPV53. This suggested that major
differences exist in the abilities to induce degradation of PDZ domain
proteins by different E6 proteins. While the high risk prototypes
HPV16 and 18 and the low-risk prototypes HPV6 and 11 behaved in
our experiments as described (Gardiol et al., 1999; Glaunsinger et al.,
2000), other high risk types such as 56 and 66 were unable to degrade
these targets, whereas HPV70 and 82 which are low-risk and possibly
high-risk, respectively, in vivo degraded both targets.
Binding of E6 proteins to E6AP, hDlg and Magi1
To further validate our ﬁndings, we investigated the direct
interaction of E6 proteins with PDZBD target proteins by in vitro
binding assays. The E6 genes of HPV6,11,16,18, 54, 56, 58, 61, 66, 70 and
82were expressed asmaltose binding protein fusionproteins (MBP) in
E. coli and afﬁnity-puriﬁed via an amylose resin. All MBP-E6 fusion
proteins were soluble and could be expressed in similar amounts and
purity. Similar amounts of E6 fusion proteins as judged by Coomassie-
stained gels were incubated with whole cell extracts derived from
HEK293Tcells, which express signiﬁcant amounts of the E6 interaction
partners p53, E6AP, hDlg, Magi1 and hScrib andwere then analyzed by
immunoblotting for retention of these E6 interaction partners. We
have recently demonstrated that all E6 proteins derived fromhigh-risk
HPVs, low-risk HPV70 and the possibly high-risk HPV82 degrade p53
in vitro (Hiller et al., 2006). Therefore, we tested the MBP-E6 fusion
proteins for binding to p53 and E6AP to validate their functionality. E6
proteins of types 16,18, 56, 58, 66, 70 and 82 bound strongly to p53 and
higher-molecular weight forms of p53, which most likely representubiquitinated p53 molecules (Fig. 2A). In contrast, the E6 proteins of
HPV6, 11, 54 and 61 bound only minimally stronger to p53 than MBP
alone and higher molecular weight forms of p53 were never detected.
The interaction with E6AP was a common feature of all E6 proteins
tested with the exception of HPV6 (Fig. 2A). Interestingly, only E6
proteins that interactedwith highermolecular forms of p53 interacted
also with higher molecular forms of E6AP indicating ubiquitination of
E6AP as a consequence of the interaction with E6 and p53 (Fig. 2A).
Taken together, a good correlationwas observed between the ability to
induce degradation of p53 in reticulocyte lysates (Hiller et al., 2006)
and binding to highermolecular weight forms of p53 and E6AP in vitro
indicating that the MBP-E6 fusion proteins are functional. Interest-
ingly, no major differences in binding to p53 or E6AP were observed
between high risk HPV types 16,18, 56, 58, 66, low-risk type 70 and the
possibly high-risk type 82.
The E6 proteins of HPV 16, 18, 56, 58, 70 and 82, but not of HPV 6,
11, 54, 61 and 66 interacted with hDlg and Magi1 (Fig. 2A).
Furthermore, it appeared that HPV16, 18, 58, 70 and 82 were capable
of binding to both the 130 kDa and the 120 kDa isoform of Magi1,
whereas high-risk 56E6 only bound to the 120 kDa isoform (Fig. 2A).
These experiments suggested that the lack of degradation of hDlg or
Magi1 in vitro by high-risk 66E6 is due to a lack of interaction. On the
other hand the high-risk 56E6 protein interacts with both proteins,
but does not induce degradation of hDlg or Magi1 for unknown
reasons. To extend these ﬁndings, we also tested binding of high-risk
HPV56 and 66 E6 proteins to the PDZ domain protein hScrib, which
has been shown to be bound by high-risk HPV16, 18 and 39 E6
proteins (Nakagawa and Huibregtse, 2000; Thomas et al., 2005). As
can be seen in Fig. 2B, consistent with previously described results, the
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extracts. Interestingly, low-risk 70E6 was similarly able to interact
with hScrib, whereas high-risk 56E6 only weakly interacted and high-
risk 66E6 failed to do so (Fig. 2B). These results demonstrate that
HPV66 despite being categorized as high-risk in vivo appears to be
unable to interact with three different PDZ proteins whereas the low-
risk HPV70 strongly interacted with all PDZ proteins tested.
Magi1 and hDlg levels in HPV-immortalized keratinocytes
We have recently described that the transfection of HPV56, 58, 66
and 82 genomes results in the immortalization of human keratino-
cytes (Hiller et al., 2006). Since no recombinant full-length HPV70
genome is currently available to test its immortalization activities, we
cloned the HPV70 E6/E7 genes into the retroviral transfer vector
pLXSN and infected normal human keratinocytes with recombinant
retroviruses. As controls retroviruses encoding E6/E7 derived from
high-risk HPV16 and 56 were used. Four independent infections of
normal human keratinocytes from two different donors with
LXSN70E6/E7 retroviruses resulted in immortalized keratinocytes
similar to HPV16 and 56. HPV70E6/E7 cell lineswere selected for G418
resistance and subsequently cultivated for more than 10 passages
(∼40 population doublings) without a loss of viability after LXSN-
transduced cells stopped growing. Furthermore, cells were cryocon-
served at different passages and cultivated again without loss of
viability or signs of crisis. This establishes for the ﬁrst time that the
low-risk HPV70 encodes oncogenes that result in the immortalization
of normal cells. To conﬁrm that the E6 and E7 genes are present and
expressed in these cell lines, genomic DNA and RNA was analyzed by
PCR. As can be seen in Fig. 3C, the E6 and E7 genes of high-risk HPV16
or low-risk HPV70 are present in the respective cell lines and are
actively transcribed giving rise to the unspliced E6 coding and the
spliced E7 coding RNAs (Fig. 3C). We then used the 70E6/E7 cell linesFig. 3. Protein levels of hDlg andMagi1 in HPV-positive cells. Whole cell extracts fromnormal
HPV82 genomes or by the E6/E7 genes of HPV70 were analyzed by immunoblotting for the p
and corrected forα-tubulin levels and are shown relative to the protein amounts present in N
indicate the error of the mean. (C) The presence of HPV16 and 70 E6/E7 DNA sequences and t
HPV type speciﬁc oligonucleotides. Products were visualized by agarose gel electrophoresisas well as cells immortalized by transfection of the high-risk HPV18,
56, 58, 66 and the possibly high-risk HPV82 genomes to determine the
amounts of the PDZ domain proteins hDlg and Magi1 by immuno-
blotting. The levels of hDlg relative to α-tubulin were moderately
reduced in HPV18-, HPV70- and HPV82-positive cells whereas no
changes could be observed in HPV56-, HPV58- and HPV66-positive
cells compared to normal keratinocytes (Fig. 3A). Magi1 levels were
strongly reduced by high-risk HPV18 and low-risk HPV70, moderately
reduced by high-risk HPV58, 66 and possibly high-risk 82 and
unchanged by high-risk HPV56 (Fig. 3B). Since HPV56 E6 bound to
hDlg, but did not reduce the protein amounts in vitro or in tissue
culture, we performed immunoﬂuorescence analyses to determine if
the protein localization was changed. As can be seen in Fig. 4, hDlg
localizes to the cell membrane and gives a weak cytoplasmic signal in
normal keratinocytes. In HPV18-positive cells, localization is similar,
but due to the decreased protein amounts theweak cytoplasmic signal
was absent. In HPV56-positive cells, hDlg also localizes mainly to the
cell membrane and a weak cytoplasmic staining comparable to
normal keratinocytes was observed. This suggested that the localiza-
tion of hDlg is unchanged by the presence of high-risk HPV56 proteins.
Discussion
A large body of epidemiological evidence suggests that only
certain HPV types have the ability to cause cervical cancer in vivo,
whereas phylogenetically closely related types do so at a very low
frequency (de Villiers et al., 2004; Munoz et al., 2006; Narechania et
al., 2005). Many studies have compared the activities of high-risk
HPV16 (species α9) and HPV18 (species α7) with low-risk HPV6 and
11 (both species α10), which are at the level of individual viral genes
very different viruses (de Villiers et al., 2004; Narechania et al., 2005).
These comparisons demonstrated that the high-risk HPV16- and 18-
encoded oncogenes E6 and E7 are, in contrast to low-risk HPV6 and 11keratinocytes (NHK), keratinocytes immortalized by HPV18, HPV56, HPV58, HPV66 and
resence of hDlg (A) or Magi1 (B). Signal intensities of hDlg or Magi1 were quantitated
HKs. The data represent the average from three independent experiments and error bars
ranscripts in G418-selected cell lines was analyzed by PCR and RT-PCR using pLXSN and
and ethidium bromide staining.
Fig. 4. Immunoﬂuorescence analysis of hDlg in HPV-positive keratinocytes. Cells were grown on glasbottom culture dishes in E-medium in the presence of feeder cells, ﬁxed with
paraformaldehyde and stained with anti-hDlg antibody and a Cy3-labeld secondary antibody. Cells were counterstained with DAPI to visualize nuclei.
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modulators of cell growth, differentiation and apoptosis (Munger et
al., 2004). The E6 proteins of HPV16 and 18 enhance the immortaliza-
tion of normal keratinocytes by E7 (Halbert et al., 1991). This is due to
the interaction of HPV16 and 18 E6 proteins with p53 and the
ubiquitin ligase E6AP which results in the targeted degradation of p53
in cells (Scheffner et al., 1990). In addition, the interaction of HPV16
E6 with E6AP also contributes, at least partially, to the activation of
telomerase (Gewin et al., 2004; Liu et al., 2005). This has led to the
notion that in vitro immortalization of normal human keratinocyte by
high-risk HPV16 and 18 oncoproteins correlates directly with the
ability to induce carcinomas in vivo. Our recently published analyses
of 19 different HPV types has questioned this model as HPV53 and 82
have immortalizing activity and degrade p53 (Hiller et al., 2006).
These virus types are regarded as possibly high-risk, but are found in
cervical cancer only at frequencies comparable to low-risk HPV 6 and
11 (Munoz et al., 2006). We have now demonstrated that also the E6/
E7 genes of HPV70, which is regarded as low-risk (Munoz et al.,
2006), immortalize normal human foreskin keratinocytes as efﬁ-
ciently as the E6/E7 genes from high-risk HPV16 or 56. However, it is
currently unclear whether immortalizing capabilities of HPVs are
inﬂuenced by the tissue source of keratinocytes. In addition, 70E6
bound (Fig. 2A) and degraded p53 comparable to 16E6 and 18E6
(Hiller et al., 2006). Since immortalization of normal keratinocytes,
binding to p53 (Fig. 2) or degradation of p53 by E6 proteins shown
previously (Hiller et al., 2006) does not correlate with carcinogenic
behavior in the genital tract we have also investigated the binding of
PDZ domain proteins to E6 proteins as a p53-independent functionthat may contribute to carcinogenicity in vivo. In contrast to binding
to p53 and E6AP, which appears to be a common feature of HPV types
that belong to species α5, α6, α7 and α9, we ﬁnd that the E6 of the
high-risk HPV66 does not bind to hDlg, Magi1 or hScrib. Similarly, the
closely related high risk HPV56E6 only binds one isoform of Magi1
and weakly to hScrib. On the other hand the E6 proteins from low-risk
HPV70 and possibly high-risk HPV82 bound indistinguishable from
high-risk HPV16 and 18 E6 proteins to Magi1 and hDlg and induced
their degradation. Since HPV56 and 66 are found at slightly increased
frequencies compared to HPV70 and 82 in cervical cancer (Smith et
al., 2007), these data suggest that the ability to bind to and degrade to
hDlg and Magi1 does not correlate with carcinogenic potential in vivo.
Furthermore, in HPV70-positive cell lines, the levels of hDlg and
Magi1 were reduced to a similar extent as in HPV18-postive cells. We
cannot at this point exclude that other PDZ domain interactors
described for 16E6 and 18E6 account for in vivo differences in
carcinogenic potential between HPV16, 18 and HPV70. This seems,
however, rather unlikely as the residues of the PDZBD of 18E6 and
70E6 are identical (RRETQV) (Zhang et al., 2007).
On the other hand, our analyses suggest that the immortalization
of normal keratinocytes, binding to E6AP and p53 and its degradation
are a conserved feature of all HPV types able to cause cervical cancer
in vivo. It appears therefore that immortalization activities of the viral
oncogenes seem to be necessary, but not sufﬁcient to cause cancer in
vivo. Since more than 20 binding partners aside from p53, E6AP, hDlg,
Magi1 and hScrib have been described for the HPV16 E6 protein
(Wise-Draper andWells, 2008), it is possible that one ormore of these
binding partners account for carcinogenicity in humans. In addition,
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it is unclear if other cervical cancer causing HPVs have the same
abilities (Klingelhutz et al., 1996). However, binding of E6 to E6AP has,
at least by some groups, been implicated in the activation of
telomerase (Bedard et al., 2008; Gewin et al., 2004). Since all
investigated E6 proteins from high risk and closely related HPV
types bound similarly to E6AP (Fig. 2), it is possible that telomerase
will be activated at least to some extent by these types. It is of course
also possible that the carcinogenic difference is only due to E7, which
also interacts with a large number of cellular interactors (Wise-Draper
andWells, 2008). Interestingly it has been recently published that the
E7 proteins of the possibly high-risk HPV26, 53 and of high-risk 66 are
less biologically active than the HPV16 E7 protein (Mansour et al.,
2007). However, in our experiments when using constructs expres-
sing both E6 and E7 or viral genomes no obvious differences in growth
behavior of HPV-positive keratinocytes were evident.
In our previous published work, we showed that binding and
degradation of p53 does not correlate with epidemiologic risk
classiﬁcation (Hiller et al., 2006). Analysis of two of the most
intensively studied interaction partners of the PDZBD of E6, Magi-1
and hDLG, as well as the ubiquitin ligase E6AP indicate that neither
binding of E6 to E6AP, to the PDZ domain proteins Magi1 and hDlg nor
the immortalization of normal human cells seem to be a predictor for
carcinogenic behavior of HPV in the cervix.
Materials and methods
Plasmids
The E6 encoding plasmids used for in vitro transcription and
translation have been previously described (Hiller et al., 2006).
Expression constructs for FLAG-Magi1c and hDlg in pcDNA3 were
generously provided by Lawrence Banks (Gardiol et al., 1999; Glaun-
singer et al., 2000). The E6 and E7 genes of HPV56 and 70 were
ampliﬁed by PCR using the cloned HPV56 genome or HPV70-positive
patient samples as templates and speciﬁc primers to add EcoRI and
BamHI restriction sites. PCR products were cloned between the EcoRI
and BamHI sites of plasmid pLXSN (Clontech, Heidelberg, Germany)
and veriﬁed by sequencing. The sequences of the HPV70 E6/E7 genes
cloned independently from two different patient samples were both
identical to the E6/E7 sequences of the HPV70 complete genome
(Genbank U21941). Plasmid pLXSN16E6/E7 was kindly provided by
Denise Galloway (Halbert et al., 1991).
HPV E6 geneswere cloned into the pMal-c2x plasmid (NEB, Frankfurt,
Germany) via the XmnI or EcoRI and the PstI or HindIII site yielding pMal-
c2X-HPVE6 fusion proteins. After sequencing, the plasmids were
transformed intoE. coliBL21DE3Rosetta 2 to allow for protein expression.
Cell culture
Cell lines containing full-length HPV genomes have been pre-
viously described (Hiller et al., 2006). Normal human foreskin
keratinocytes (NHK) were isolated from neonatal foreskins and
cultivated in complete keratinocyte serum free medium (K-SFM,
Invitrogen, Karlsruhe,Germany) supplemented with gentamycin
(Invitrogen, Karlsruhe, Germany). Retrovirally-transduced and HPV-
transfected cell lines were maintained in E-medium on mitomycin C-
treated NIH3T3 J2 ﬁbroblasts as described (Frattini et al., 1996).
HEK 293T cells were maintained in DMEM supplemented with
gentamycin and 10% fetal bovine serum.
Generation of E6/E7-expressing keratinocytes
High-titered amphotropic recombinant retroviruses were gener-
ated by transient transfection of the retroviral vectors into Phoenix
cells (ATCC # SD 3443) using the calcium phosphate precipitationmethod. Forty-eight hours after transfection, the cell culture super-
natants were ﬁltered through 0.2 μm sterile ﬁlters, and a 3 ml aliquot
was mixed with 5 μg/ml polybrene (hexadimethrine bromide, Sigma-
Aldrich Chemie Gmbh,Munich, Germany). Themixturewas incubated
for 4 h with NHK cells grown on 100-mm-diameter dishes to 70%
conﬂuency. Then 4 ml of K-SFM were added. 24 h post infection the
NHK were transferred to mitomycinC-treated NIH3T3 J2 ﬁbroblasts as
feeder cells in E-Medium as described earlier (Frattini et al., 1996).
G418 selection (100 μg/ml) was applied for 14 days. Stable G418-
resistant cell lines were maintained in E-Medium and long-term
growth was monitored. DNA was extracted from cell lines using the
EZ1 DNA Tissue Kit and a Qiagen workstation (Qiagen, Hilden,
Germany) and probed for retroviral integration by PCR using
pLXSN_for (5′-CCCTTGAACCTCCTCGTTCGACC-3′) and pLXSN_rev
(5′-GAGCCTGGGGACTTTCCACACCC-3′) primers and subsequent
sequencing. Transcription of the E6/E7 sequences was veriﬁed by
reverse transcription (QuantiTect Rev. Transcription Kit, Qiagen,
Hilden, Germany) followed by PCR using type speciﬁc forward
primers for HPV 16 (5′-ATGTTTCAGGACCCACAGGA-3′) or 70 (5′-
ATGGCGCGATTTCCCAATCC-3′) and the pLSXN_rev primer.
In vitro degradation assays
pcDNA3-MAGI-1c and pcDNA3-hDlg or pcDNA3-E6 plasmids
were transcribed and translated in vitro using the TNT coupled
rabbit reticulocyte lysate system (Promega, Mannheim, Germany)
and [35S]-methionine (N1000 Ci/mmol) or [35S]-cysteine
(N1000 Ci/mmol) (GE Healthcare Europe GmbH, Munich, Germany),
respectively, according to the manufacturer's instructions. A 7 μl
aliquot of each translation reaction was separated by SDS-poly-
acrylamide gels, exposed to image screens and the amount of labeled
proteins was then quantiﬁed by measuring the signal intensities of
protein bands with a BAS-1800 PhosphoImager (Fujiﬁlm, Duessel-
dorf, Germany) and the AIDA software version 2.0 (Raytest GmbH,
Straubenhardt, Germany). After equalizing for the different amounts
of cysteines or methionines, respectively, the results of this
quantitation were used to mix target proteins with E6 proteins at a
ratio of 1:1. Volumes were adjusted using water-primed lysate.
Reaction mixtures were incubated at 30 °C for three hours. The
residual proteins were resolved by SDS-polyacrylamide gels and
visualized and quantiﬁed as described above.
Maltose binding protein pulldown assays
Escherichia coli BL21 DE3 Rosetta2 expressing E6-MBP fusion
protein were grown to an OD600 of 0.6, shifted to 20 °C and then
0.5 mM IPTG was added for 1 h. Bacteria were harvested by
centrifugation, resuspended in 1 ml of TMN buffer (50 mM Tris pH
8.0, 12.5 mM MgCl2, 0.1% Igepal CA-630, 0.1% DTT) and disrupted by
ultrasonication (Bandelin Sonoplast UW2200) on ice. Cleared super-
natants were incubated with 50 μl of amylose agarose beads (NEB,
Frankfurt, Germany) for 1 h at 4 °C and then extensively washed with
TMN buffer. HEK293 cells were harvested by trypsination and lysed in
NP40 lysis buffer (130 mM NaCl, 50 mM Tris pH 8.0, 1 mM EDTA, 1%
Igepal CA-630, 1 mM DTT). Cell lysates equivalent to 3×107 cells were
incubated with immobilized MBP-E6 fusion proteins for 2 h at 4 °C.
Subsequently, the resin was washed several times with TMN buffer
and the retained proteins were eluted with TMN buffer containing
20 mM maltose and analyzed by Western blotting.
Western blot analysis
Total cell extracts were prepared with NP40 lysis buffer or M-PER
reagent (Perbio Science Deutschland GmbH, Bonn, Germany),
separated on SDS-polyacrylamide gels, transferred to nitrocellulose
and cut in half. The upper part was probed with a Magi1 antibody
386 P. Muench et al. / Virology 387 (2009) 380–387(Sigma-Aldrich, M5691) or an hDlg antibody (BD Bioscience, 610874)
respectively, and the lower part with aα-tubulin antibody (Santa Cruz
Biotechnology) and the respective secondary antibodies conjugated to
horseradish peroxidase. Blots were developed with Supersignal West
Dura or Femto (Perbio Science Deutschland GmbH, Bonn, Germany)
and visualized on the Fluor-S Max MultiImager (Biorad, Munich,
Germany). Band intensities were quantiﬁed by the Quantity One
Quantitation software package (version 4). Target protein signals
were normalized against the respective α-tubulin levels.
For MBP pull down assays, total cell extracts of HEK293T cells and
eluted proteins were run on 6 to 10% SDS-polyacrylamide gels and
transferred to nitrocellulose. The membranes were probed with E6AP
(Santa Cruz Biotechnology, H-182), p53 (Santa Cruz Biotechnology, sc-
126(DO-1)), hScrib (Abcam, ab6049), hDlg or Magi1 antibodies. Blots
were incubated with the respective secondary antibodies and
analyzed as described above.
Immunoﬂuorescence microscopy
For indirect immuno-ﬂuorescence microscopy analysis, cells were
grown on MatTek Glasbottom Culture Dishes (MatTek Corporation,
Ashland, MA, USA), ﬁxed in 2% paraformaldehyde for 10 min and
incubated with hDlg antibody in PBS/3% BSA for one hour at RT. Cells
were subsequently washed with PBS and incubated with Cy3-
conjugated anti-mouse IgG antibodies. Unbound antibody was
removed by extensive washing with PBS; DAPI in PBS was brieﬂy
added to stain for DNA and then unbound DAPI was removed by
washing with PBS. Fluorescence signals were visualized with a Zeiss
Axiovert 200M microscope featuring the apotome technique and the
respective ﬂuorescence ﬁlter sets for DAPI and Cy3. Pictures were
taken with an Axiocam MRm camera and processed with Axiovision
software version 4.3 (Carl Zeiss MicroImaging GmbH, Germany).
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